Advanced differentiated thyroid cancer: when to stop radioiodine?.

MedStar author(s):
Citation: The Quarterly Journal of Nuclear Medicine. 63(3):267-270, 2019 Sep.PMID: 31271271Institution: MedStar Washington Hospital CenterDepartment: Medicine/Nuclear MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Iodine Radioisotopes/tu [Therapeutic Use] | *Thyroid Neoplasms/pa [Pathology] | *Thyroid Neoplasms/rt [Radiotherapy] | Disease Progression | Humans | Treatment OutcomeYear: 2019ISSN:
  • 1824-4785
Name of journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...Abstract: Radioiodine (RAI) is a pivotal important treatment for patients with metastatic differentiated thyroid cancer (DTC). In order to determine when a patient will no longer respond to RAI, multiple classifications have been described to categorize a patient as radioiodine refractory (RAI-R). Current classifications, although very useful, are problematic and controversial and cannot be merely applied in the context of individualized patient management. In addition, classifications on how to define RAI-R disease are continuosly evolving as more studies are published and managing physicians better understand the limitations and confounding factors of present classifications. Accordingly, each patient should be individually managed with a good understanding of the limitations of the various classifications, assessing the many other factors that affect the patient's specific clinical situation and delivering appropriate individualized patient care.All authors: Giovanella L, van Nostrand DOriginally published: The Quarterly Journal of Nuclear Medicine. 2019 Jul 01Fiscal year: FY2020Digital Object Identifier: Date added to catalog: 2019-07-24
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 31271271 Available 31271271

Radioiodine (RAI) is a pivotal important treatment for patients with metastatic differentiated thyroid cancer (DTC). In order to determine when a patient will no longer respond to RAI, multiple classifications have been described to categorize a patient as radioiodine refractory (RAI-R). Current classifications, although very useful, are problematic and controversial and cannot be merely applied in the context of individualized patient management. In addition, classifications on how to define RAI-R disease are continuosly evolving as more studies are published and managing physicians better understand the limitations and confounding factors of present classifications. Accordingly, each patient should be individually managed with a good understanding of the limitations of the various classifications, assessing the many other factors that affect the patient's specific clinical situation and delivering appropriate individualized patient care.

English

Powered by Koha